AUS
NZ
UK
CA
USA
IND
Highlights
- Neuren Pharmaceuticals secures $50 million from FDA voucher sale.
- The sale is linked to Acadia Pharmaceuticals' Rett syndrome treatment, DAYBUE.
- Funds are expected to support Neuren’s ongoing neurodevelopmental research.
Neuren Pharmaceuticals (ASX:NEU) has announced a major financial gain as a result of the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its U.S. partner, Acadia Pharmaceuticals (NASDAQ:ACAD). This transaction, valued at $150 million, is expected to provide Neuren with approximately $50 million from the net proceeds. The PRV, a significant asset in the pharmaceutical industry, was granted to Acadia by the U.S. Food and Drug Administration (FDA) following the approval of DAYBUE (trofinetide), a breakthrough treatment for Rett syndrome in young patients.
The FDA's Rare Pediatric Disease Program awards PRVs to companies developing treatments for severe pediatric diseases, encouraging advancements in areas with limited therapeutic options. The voucher offers a unique benefit: it allows the holder to expedite the review process for a future drug, cutting down the standard FDA review time from ten to six months. This accelerated review can be critical for pharmaceutical companies aiming to bring treatments to market swiftly. PRVs can be used by the company holding them or sold to other organizations seeking quicker FDA approval for their drug candidates.
DAYBUE, the drug behind the voucher's issuance, is designed to treat Rett syndrome, a rare neurological disorder that primarily affects young females. Rett syndrome often appears after an initial period of normal development, followed by a gradual loss of motor and communication skills, causing challenges with movement, speech, and breathing. Patients diagnosed with Rett syndrome generally require ongoing support due to the disorder’s severe impact on their lives. DAYBUE, marketed by Acadia, targets the underlying neurodevelopmental issues associated with Rett syndrome, offering symptom relief by addressing specific inflammatory and neurological pathways.
The partnership between Neuren and Acadia has paved the way for the global development and commercialization of DAYBUE. Under this agreement, Neuren receives a share of the proceeds from the sale of the PRV, estimated to amount to $50 million. This funding is anticipated to bolster Neuren's ongoing research initiatives in neurodevelopmental therapies, supporting advancements in treatments for other rare conditions.
Neuren’s CEO, Jon Pilcher, expressed optimism about the partnership's benefits, noting that the funds obtained from this voucher sale will allow the company to advance its portfolio of neurodevelopmental treatments. The success of this partnership with Acadia underscores the impact of PRVs in promoting innovation and investment in pediatric disease research.
